Pnc Financial Services Group, Inc. Revance Therapeutics, Inc. Transaction History

Pnc Financial Services Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$4.65 - $9.31 $153 - $307	-33 Reduced 13.58%	210 $1,000
Q4 2023 Feb 09, 2024	SELL	$5.81 - $11.2 $377 - $728	-65 Reduced 21.1%	243 $2,000
Q3 2023 Nov 13, 2023	SELL	$11.47 - $25.07 $1,387 - $3,033	-121 Reduced 28.21%	308 $3,000
Q2 2023 Aug 11, 2023	SELL	$24.7 - $37.61 $5,458 - $8,311	-221 Reduced 34.0%	429 $10,000
Q4 2022 Feb 10, 2023	BUY	$18.32 - $30.66 $3,260 - $5,457	178 Added 37.71%	650 $11,000
Q1 2022 May 12, 2022	SELL	$12.36 - $20.31 $44,446 - $73,034	-3,596 Reduced 88.4%	472 $9,000
Q4 2021 Feb 11, 2022	BUY	$12.46 - $27.87 $44,644 - $99,858	3,583 Added 738.76%	4,068 $66,000
Q1 2021 May 07, 2021	BUY	$24.03 - $29.97 $7,689 - $9,590	320 Added 193.94%	485 $13,000
Q2 2020 Aug 07, 2020	BUY	$12.6 - $26.55 $415 - $876	33 Added 25.0%	165 $4,000
Q4 2019 Feb 07, 2020	BUY	$11.66 - $20.15 $979 - $1,692	84 Added 175.0%	132 $2,000
Q4 2017 Feb 09, 2018	BUY	$24.55 - $36.3 $1,178 - $1,742	48	48 $0

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.